Indegene Ltd

Meeting Details

• Dates: 24–25 August 2026; times not specified.
• 24 Aug 2026: Online 1x1 with MFS International Singapore.
• 24 Aug 2026: Online 1x1 with ASK Investment Managers.
• 24 Aug 2026: Online 1x1 with Mirae Mutual Fund.
• 25 Aug 2026: In-person 1x1 with Goldman Sachs Asset Management, Bengaluru.
• 25 Aug 2026: Online 1x1 with Seven Canyon Advisors.

Participants

• Company officials will participate in meetings.
• Company Secretary and Compliance Officer to represent Indegene.

Purpose

• Intimation of Schedule of Investor / Analyst meetings.

Additional Notes

• No unpublished price sensitive information will be shared.
• Information will be available on the company website.

Litigation status

• Definitive settlement terms substantially concluded; execution authorized after clarifications on August 18, 2026.
• Settlement with Progressive Health and Rehab Corp. in the U.S. District Court, New Jersey.

Settlement framework

• Maximum settlement fund USD 4.72 million; USD 250 per eligible claim.
• Settlement is claims-made; actual payouts depend on valid/approved claims; no upfront funding required.

Administration and timing

• Notice via fax or first-class mail; administration cost about USD 42,559.
• Next steps: execution, court filing, preliminary approval, class notice, and final court approval.

Impact and governance

• Settlement does not admit liability; accounting impact to be determined under applicable standards.

AGM Details

• AGM held on August 13, 2026 at 4:30 PM IST via VC/OAVM.
• Quorum achieved via video conference; remote e-voting available; no record date stated.

Resolutions & Outcomes

• Item 1: Adoption of standalone and consolidated financial statements — Passed.
• Item 2: Declaration of final dividend — Passed; INR 2.25 per share proposed.
• Item 3: Appointment of Manish Gupta as director liable to retire by rotation — Passed.
• Item 4: Appointment of Dr. Sanjay Suresh Parikh as director liable to retire by rotation — Passed.
• Item 5: Appointment of Jill Mary DeSimone as Independent Director — Passed.

Dividends & Capital Allocation

• Final dividend of INR 2.25 per share was recommended by the board.
• Strong cash flow supports continued dividend sustainability and capital discipline.

Acquisitions & Strategic Outlook

• BioPharm acquisition completed; total cost around INR 887 crores; USD 104 million.
• USD 65 million paid at closing; USD 19 million earn-out due 2027.
• Two European acquisitions completed and integrated.
• FY26 revenue exceeded INR 3,500 crores; quarterly revenue over INR 1,000 crores.
• Board to pursue further AI-led investments and selective acquisitions if returns justify.

Auditors & Governance

• Statutory auditor Deloitte Haskins & Sells issued unqualified opinions on financials.
• Secretarial auditor qualifications noted; management responses published in annual report.

Director appointment

• Ms Jill Mary De Simone appointed Independent Director for a 3-year term from 22-01-2026 to 21-01-2029.
• Profile: Biopharma executive; former Merck US Oncology President; governance and board experience.
• Relationships: Not related to any other Director.
• Not debarred by SEBI or other authorities.

AGM Details and Outcomes

• AGM held on 13 August 2026 at 4:30 PM IST via VC/OAVM.
• All resolutions were passed with requisite majority.
• Combined voting results and Scrutinizer's Report enclosed as Annexures A and B.
• Documents including results are available on the company's website.

Meeting Details

• Date: 19 August 2026; time not disclosed.
• Type/Mode: 1x1 in-person meeting.
• Organizer: Buoyant Capital.
• Participants: Company officials to participate (roles not specified).
• Purpose: Investor/analyst meeting.
• Location: Mumbai, Maharashtra, India.

AGM Details

• Date and time: 13 August 2026, 4:30 PM to 6:42 PM IST.
• Mode: VC/OAVM; no physical attendance; proxies not applicable except corporate reps.

Key Resolutions and outcomes

• Adopt Audited Financial Statements for FY ended 31 March 2026; Ordinary; passed.
• Declare final dividend of Rs 2.25 per equity share; Ordinary; passed.
• Appoint Manish Gupta as Director, liable to retire by rotation; Ordinary; passed.
• Appoint Dr. Sanjay Suresh Parikh as Director, liable to retire by rotation; Ordinary; passed.
• Appoint Ms. Jill Mary De Simone as Independent Director; Special; passed.

Dividend

• Final dividend per equity share Rs 2.25 approved.

Director changes

• Manish Gupta appointed Director, liable to retire by rotation.
• Dr. Sanjay Suresh Parikh appointed Director, liable to retire by rotation.
• Jill Mary De Simone appointed Independent Director.

Auditor updates

• No changes to statutory/secretarial auditors reported.

Meeting Details

• Date: 17 August 2026.
• Meeting type & mode: One-on-one, in-person meetings.
• Officials of Indegene to meet investors; no personal names provided.
• Counterparties: Karma Capital; ICICI Prudential Mutual Fund; SBI Mutual Fund; Enam Holdings; Quant Mutual Fund.
• Location: Mumbai, Maharashtra, India.
• Purpose: Schedule of Investor/Analyst meetings with investors.

Meeting Details

• 17 July 2026, Mumbai; in-person 1x1 investor meeting with Karma Capital; purpose: investor interaction.
• 17 July 2026, Mumbai; in-person 1x1 investor meeting with ICICI Prudential Mutual Fund; purpose: investor interaction.
• 17 July 2026, Mumbai; in-person 1x1 investor meeting with SBI Mutual Fund; purpose: investor interaction.
• 17 July 2026, Mumbai; in-person 1x1 investor meeting with Enam Holdings; purpose: investor interaction.
• 17 July 2026, Mumbai; in-person 1x1 investor meeting with Quant Mutual Fund; purpose: investor interaction.
• Company participants: officials of Indegene to meet investors.

Transaction details

• Target Company: Indegene Limited.
• Disclosing party: Seller BPC Genesis Fund I-A SPV Limited; PAC same; not promoter.
• Transaction Type: Open market sale of voting shares.
• Pre-Transaction Holding: 7,190,255 voting shares (2.986%).
• Encumbrances pre: 0.
• Transaction Details: 7,190,255 shares sold; 2.986%; equity; open market on NSE.
• Post-Transaction Holding: 0 voting shares (0%); encumbrances: 0.
• Date of Transaction: 6 August 2026.
• Share Capital Context: Pre/post 240,807,964; diluted after 241,466,564.